Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis

The approval of bedaquiline (BDQ) for the treatment of tuberculosis has generated substantial interest in inhibiting energy metabolism as a therapeutic paradigm. However, it is not known precisely how BDQ triggers cell death in Mycobacterium tuberculosis (Mtb). Using (13)C isotopomer analysis, we sh...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Nat Commun
मुख्य लेखकों: Mackenzie, Jared S., Lamprecht, Dirk A., Asmal, Rukaya, Adamson, John H., Borah, Khushboo, Beste, Dany J. V., Lee, Bei Shi, Pethe, Kevin, Rousseau, Simon, Krieger, Inna, Sacchettini, James C., Glasgow, Joel N., Steyn, Adrie J. C.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Nature Publishing Group UK 2020
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7705017/
https://ncbi.nlm.nih.gov/pubmed/33257709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-19959-4
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन